Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Bio-Path Holdings (BPTH)

Bio-Path Holdings (BPTH)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.1790 +0.0190 (+11.87%) 04/04/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.1790 unch (unch) 15:26 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.1510
Day High
0.1790
Open 0.1510
Previous Close 0.1600 0.1600
Volume 31,800 31,800
Avg Vol 55,125 55,125
Stochastic %K 39.42% 39.42%
Weighted Alpha -91.59 -91.59
5-Day Change +0.0238 (+15.34%) +0.0238 (+15.34%)
52-Week Range 0.1210 - 7.6699 0.1210 - 7.6699
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 1,487
  • Shares Outstanding, K 8,308
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,890 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.99
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.91
  • Most Recent Earnings $-0.87 on 11/14/24
  • Next Earnings Date 05/21/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 1
  • High Estimate -0.38
  • Low Estimate -0.38
  • Prior Year -4.88
  • Growth Rate Est. (year over year) +92.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1450 +23.45%
on 03/13/25
Period Open: 0.1738
0.1999 -10.46%
on 03/20/25
+0.0052 (+2.99%)
since 03/04/25
3-Month
0.1210 +47.93%
on 02/19/25
Period Open: 1.1600
1.2200 -85.33%
on 01/06/25
-0.9810 (-84.57%)
since 01/03/25
52-Week
0.1210 +47.93%
on 02/19/25
Period Open: 4.3000
7.6699 -97.67%
on 04/18/24
-4.1210 (-95.84%)
since 04/04/24

Most Recent Stories

More News
Bio-Path Holdings Reports Full Year 2024 Financial Results

BPTH : 0.1790 (+11.88%)
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

BPTH : 0.1790 (+11.88%)
Bio-Path Holdings Expands Global Patent Portfolio

BPTH : 0.1790 (+11.88%)
Bio-Path Holdings Provides Key Clinical Updates

BPTH : 0.1790 (+11.88%)
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

BPTH : 0.1790 (+11.88%)
Bio-Path Holdings Provides 2025 Clinical and Operational Update

BPTH : 0.1790 (+11.88%)
Is This Penny Stock a Buy After a 180% Rally?

Bio-Path Holdings surged 180% on promising obesity drug results. Discover why this penny stock's pivot from cancer treatments and Nasdaq delisting challenges could matter for investors.

BPTH : 0.1790 (+11.88%)
Bio-Path Holdings, Inc. Reports Promising Preclinical Results for BP1001-A as a Potential Treatment for Obesity and Type 2 Diabetes

Bio-Path Holdings reports BP1001-A shows promise for treating obesity and Type 2 diabetes by enhancing insulin sensitivity.Quiver AI SummaryBio-Path Holdings, Inc. announced promising preclinical results...

BPTH : 0.1790 (+11.88%)
Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode

The company said it has initiated animal studies to further confirm the drug’s efficacy, with plans to launch a first-in-human Phase 1 trial in 2025.

VXF : 155.35 (-5.26%)
BPTH : 0.1790 (+11.88%)
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

BPTH : 0.1790 (+11.88%)

Business Summary

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout...

See More

Key Turning Points

3rd Resistance Point 0.2163
2nd Resistance Point 0.1977
1st Resistance Point 0.1883
Last Price 0.1790
1st Support Level 0.1603
2nd Support Level 0.1417
3rd Support Level 0.1323

See More

52-Week High 7.6699
Fibonacci 61.8% 4.7862
Fibonacci 50% 3.8954
Fibonacci 38.2% 3.0047
Last Price 0.1790
52-Week Low 0.1210

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades